Journal of Angiotherapy最新文献

筛选
英文 中文
Biomarkers in Clinical Trials: From Cancer Researcher and Cancer Patient Perspective 临床试验中的生物标志物:从癌症研究人员和癌症患者的角度
Journal of Angiotherapy Pub Date : 2022-12-24 DOI: 10.25163/angiotherapy.6313c
{"title":"Biomarkers in Clinical Trials: From Cancer Researcher and Cancer Patient Perspective","authors":"","doi":"10.25163/angiotherapy.6313c","DOIUrl":"https://doi.org/10.25163/angiotherapy.6313c","url":null,"abstract":"","PeriodicalId":154960,"journal":{"name":"Journal of Angiotherapy","volume":"4 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-12-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"121042529","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Developing Affordable Cancer Therapeutics in Low and Middle Income Countries 在低收入和中等收入国家开发负担得起的癌症治疗方法
Journal of Angiotherapy Pub Date : 2022-12-24 DOI: 10.25163/angiotherapy.637c
{"title":"Developing Affordable Cancer Therapeutics in Low and Middle Income Countries","authors":"","doi":"10.25163/angiotherapy.637c","DOIUrl":"https://doi.org/10.25163/angiotherapy.637c","url":null,"abstract":"Over half the world’s cancers occur in Low-and-Middle-Income-Countries (LMICs), where cancer is a neglected disease. Despite significant advances in systemic anticancer therapy, many of these treatments are simple not available to the majority of the world’s cancer patients. For example, immunotherapy has changed the treatment paradigm for many cancer patients in developed countries, significantly prolonging survival and maintaining patient quality of life but at a cost that is currently unaffordable for many public health systems and patients in LMICs. We urgently need better solutions to treat patients more effectively, humanely and equitably. Drug discovery and novel drug development takes on average 10-15 years to go from bench to bedside at an average cost of USD1 billion. Repurposing of 'old' drugs for new indications can shorten this pathway substantially with significant cost savings. One strong drug repurposing candidate is artesunate, an antimalarial derived from traditional Chinese medicine that also displays anticancer properties. This drug is currently the subject of our drug repurposing programme which includes a number of cancers relevant to Malaysian needs including colorectal cancer, cervical cancer, nasopharyngeal cancer and Acute Myeloid Leukaemia. Alongside drug repurposing, platform technologies such as molecular pharming – using plants to grow cancer drugs, in particular immunotherapies and targeted monoclonal antibodies can also reduce the cost of cancer drug development significantly. Malaysia has the opportunity to lead on healthcare priorities facing LMICs, creating reverse linkage collaborations between Muslim countries through entities such as the Islamic Development Bank (which now has a Center of Excellence for Science, Technology and Innovation) in Kuala Lumpur and local governments. This also represents opportunities for technology transfer and halal sector manufacturing. Collaboration is urgently needed between academia, clinicians, patient advocate groups, governments, non-governmental stakeholders, regulators and responsible pharma to ensure equitable access to affordable cancer therapeutics for patients globally.","PeriodicalId":154960,"journal":{"name":"Journal of Angiotherapy","volume":"1 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-12-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"131100505","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Elucidating the Transcriptional Regulation and Chemosensitivity Efficacy of Terminal Differentiation Induced Non-Coding RNA (TINCR) Driver Regulator in Triple-Negative Breast Cancer (TNBC) 三阴性乳腺癌(TNBC)中末端分化诱导的非编码RNA (TINCR)驱动调节因子的转录调控及化学敏感性疗效研究
Journal of Angiotherapy Pub Date : 2022-12-24 DOI: 10.25163/angiotherapy.6318c
{"title":"Elucidating the Transcriptional Regulation and Chemosensitivity Efficacy of Terminal Differentiation Induced Non-Coding RNA (TINCR) Driver Regulator in Triple-Negative Breast Cancer (TNBC)","authors":"","doi":"10.25163/angiotherapy.6318c","DOIUrl":"https://doi.org/10.25163/angiotherapy.6318c","url":null,"abstract":"","PeriodicalId":154960,"journal":{"name":"Journal of Angiotherapy","volume":"13 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-12-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"114563599","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Targeted Delivery of Cisplatin Using RGD-Modified ZIF-90 as Delivery Vehicle 以rgd修饰的ZIF-90为载体靶向递送顺铂
Journal of Angiotherapy Pub Date : 2022-12-24 DOI: 10.25163/angiotherapy.6314c
{"title":"Targeted Delivery of Cisplatin Using RGD-Modified ZIF-90 as Delivery Vehicle","authors":"","doi":"10.25163/angiotherapy.6314c","DOIUrl":"https://doi.org/10.25163/angiotherapy.6314c","url":null,"abstract":"","PeriodicalId":154960,"journal":{"name":"Journal of Angiotherapy","volume":"202 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-12-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"133878993","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Emerging Immuno-cellular Therapy in the Treatment of Diffuse Large B-cell Lymphoma 弥漫性大b细胞淋巴瘤新出现的免疫细胞疗法
Journal of Angiotherapy Pub Date : 2022-12-24 DOI: 10.25163/angiotherapy.6311c
{"title":"Emerging Immuno-cellular Therapy in the Treatment of Diffuse Large B-cell Lymphoma","authors":"","doi":"10.25163/angiotherapy.6311c","DOIUrl":"https://doi.org/10.25163/angiotherapy.6311c","url":null,"abstract":"","PeriodicalId":154960,"journal":{"name":"Journal of Angiotherapy","volume":"17 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-12-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"121057169","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
2nd International Scientific Conference of the The Malaysian Association for Cancer Research (MACR) 马来西亚癌症研究协会(MACR)第二届国际科学会议
Journal of Angiotherapy Pub Date : 2022-12-24 DOI: 10.25163/angiotherapy.631c
{"title":"2nd International Scientific Conference of the The Malaysian Association for Cancer Research (MACR)","authors":"","doi":"10.25163/angiotherapy.631c","DOIUrl":"https://doi.org/10.25163/angiotherapy.631c","url":null,"abstract":"The Malaysian Association for Cancer Research (MACR) is proud to organize the second instalment of MACR International Scientific Conference (MSC) in partnership with Malaysian Oncological Society (MOS) and local Public & Private universities. MSC aims to provide a major convening platform for cancer research communities based locally and abroad. This two-day conference is expected to open up avenues for meaningful collaboration at the regional and global levels to promote cancer drug discovery and development through integrative research.The topics this conference will cover include but are not limited to: Novel cancer drug target identification, New cancer drug discoveries, Translational cancer medicine, Clinical trials of new cancer drugs, Diagnostic and prognostic values of new cancer markers, Cancer prevention, and Precision oncology. Download the published abstract (please click on the PDF file right side of this abstract)","PeriodicalId":154960,"journal":{"name":"Journal of Angiotherapy","volume":"76 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-12-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"124513551","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Development and Characterisation of Zerumbone-Superparamagnetic Iron Oxide Nanoparticle Co-Loaded Nanostructured Lipid Carriers as A Potential Treatment for Breast Cancer zerumbone -超顺磁性氧化铁纳米颗粒共载纳米结构脂质载体作为乳腺癌潜在治疗方法的开发和表征
Journal of Angiotherapy Pub Date : 2022-12-24 DOI: 10.25163/angiotherapy.6321c
{"title":"Development and Characterisation of Zerumbone-Superparamagnetic Iron Oxide Nanoparticle Co-Loaded Nanostructured Lipid Carriers as A Potential Treatment for Breast Cancer","authors":"","doi":"10.25163/angiotherapy.6321c","DOIUrl":"https://doi.org/10.25163/angiotherapy.6321c","url":null,"abstract":"","PeriodicalId":154960,"journal":{"name":"Journal of Angiotherapy","volume":"75 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-12-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"132028917","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cytotoxicity Effects of Selected Flavonoids in Human Ovarian Cancer Cells 黄酮类化合物对人卵巢癌细胞的细胞毒性作用
Journal of Angiotherapy Pub Date : 2022-12-24 DOI: 10.25163/angiotherapy.6317c
{"title":"Cytotoxicity Effects of Selected Flavonoids in Human Ovarian Cancer Cells","authors":"","doi":"10.25163/angiotherapy.6317c","DOIUrl":"https://doi.org/10.25163/angiotherapy.6317c","url":null,"abstract":"","PeriodicalId":154960,"journal":{"name":"Journal of Angiotherapy","volume":"8 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-12-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134227985","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Molecular Modelling Analysis of Squamocin as Potential BCL-XL Anti-apoptotic Protein Inhibitor 鳞片素作为BCL-XL抗凋亡蛋白抑制剂的分子模拟分析
Journal of Angiotherapy Pub Date : 2022-12-24 DOI: 10.25163/angiotherapy.6316c
{"title":"Molecular Modelling Analysis of Squamocin as Potential BCL-XL Anti-apoptotic Protein Inhibitor","authors":"","doi":"10.25163/angiotherapy.6316c","DOIUrl":"https://doi.org/10.25163/angiotherapy.6316c","url":null,"abstract":"","PeriodicalId":154960,"journal":{"name":"Journal of Angiotherapy","volume":"33 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-12-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"132214939","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Ferritin and High Sensitivity C-Reactive Protein (hs-CRP) may predict the COVID-19 patient’s fate 铁蛋白和高敏c反应蛋白(hs-CRP)可能预测COVID-19患者的命运
Journal of Angiotherapy Pub Date : 2022-02-01 DOI: 10.25163/angiotherapy.625319
Z. A. Kheudhier, A. Mossa
{"title":"Ferritin and High Sensitivity C-Reactive Protein (hs-CRP) may predict the COVID-19 patient’s fate","authors":"Z. A. Kheudhier, A. Mossa","doi":"10.25163/angiotherapy.625319","DOIUrl":"https://doi.org/10.25163/angiotherapy.625319","url":null,"abstract":"Objective: Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has rapidly spread worldwide. Clinical outcomes and disease severity are still unknown and can be difficult to predict. In this study, we perform a cross-sectional observational study to investigate the clinical characteristics of ferritin and high sensitivity C-reactive protein status of patients infected with COVID-19 that may predict the COVID-19 patient’s fate. Methods: A total of 106 patients (56 males and 50 females, their ages ranging from 19 to 70 years) who were confirmed to have COVID-19 by real-time RT-PCR were recruited in this study. Blood samples were withdrawn, and biochemical tests (serum ferritin and C-reactive protein) were performed. The gained data were analyzed using GraphPad Prism software. Results: Overall, the findings showed that ferritin and C-reactive protein were increased from day 1 to day 7 and then decreased on day 14 after diagnosis in patients who are released after full recovery. While they still dramatically increased from day 1 to day 7 to day 14 in those who moved to the intensive care unit or died by day 14. No gender-based differences were noted. Conclusions: These findings suggest that the patient’s fate and disease severity can be predicted at day 7 based on these two biomarkers.","PeriodicalId":154960,"journal":{"name":"Journal of Angiotherapy","volume":"23 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"128488017","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信